* Myriad Genetics Inc MYGN.OQ MYGN.O is expected to show
a
rise in quarterly revenue when it reports results on February
27 for the period ending December 31 2023
* The Salt Lake City Utah-based company is expected to
report a
9.6% increase in revenue to $194.784 million from $177.8 million
a year ago, according to the mean estimate from 12 analysts,
based on LSEG data.The company's guidance on November 6 2023,
for the period ended December 31, was for revenue between
$197.66 million and $203.41 million. (Majority SAL is on Net
Revenue basis)
* LSEG's mean analyst estimate for Myriad Genetics Inc is
for
earnings of 1 cent per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 5
"hold" and 3 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Myriad
Genetics
Inc is $23.00, below its last closing price of $23.10.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.08 -0.08 -0.03 Beat 63
Jun. 30 2023 -0.09 -0.08 -0.08 Met 5.9
Mar. 31 2023 -0.19 -0.19 -0.21 Missed -8.6
Dec. 31 2022 -0.15 -0.16 -0.12 Beat 26.5
Sep. -0.04 -0.06 -0.19 Missed -216.7
30 2022
Jun. 30 2022 0.03 0.01 0.04 Beat 300
Mar. 31 2022 -0.06 -0.07 -0.03 Beat 55.3
Dec. 31 2021 -0.01 -0.02 -0.02 Met 14.3
This summary was machine generated February 23 at 11:54 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)